Christine M. Lovly, MD, PhD is currently an Associate Professor of Medicine with tenure at the Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center. She received a B.A. in chemistry from Johns Hopkins University followed by M.D. and Ph.D. degrees as part of the Medical Scientist Training Program at Washington University in St. Louis, MO. She then completed internal medicine residency and medical oncology subspecialty training at Vanderbilt University. During her final year of fellowship, she was the Jim and Carol O'Hare Chief Fellow. She started on faculty at Vanderbilt in July 2013 as a physician scientist, splitting her time between clinical care and laboratory research. Her laboratory research is directed at understanding and developing improved therapeutic strategies for specific clinically relevant molecular subsets of lung cancer.

Dr. Lovly has received grant funding from NIH/NCI, the Conquer Cancer Foundation of the American Society of Clinical Oncology, the Sarcoma Foundation of America, the American Cancer Society, the Damon Runyon Foundation, the LUNGevity Foundation, the V Foundation, the American Association for Cancer Research, and Lung Cancer Foundation of America / International Association for the Study of Lung Cancer. She is an active member in the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (IASLC), and the American Association for Cancer Research (AACR). Her team’s work has published in high impact journals, including Cancer Discovery, Nature Medicine, Nature Communications, Journal of Clinical Oncology, Proceedings of the National Academy of Sciences, and others. She has published > 140 peer reviewed manuscripts.

Dr. Lovly is an elected member of the American Society for Clinical Investigation (class of 2017) and a member of the Editorial Board for Cancer Discovery and JCO Precision Oncology. She serves on the Scientific Leadership Boards for the GO2 Foundation for Lung Cancer Research (where she also serves as Scientific Leadership Board Director), the LUNGevity Foundation, and the Lung Cancer Research Foundation. Dr. Lovly serves on the National Comprehensive Cancer Network (NCCN) guidelines panel for Non-Small Cell Lung Cancer and is co-chair of the ECOG-ACRIN Thoracic Translational Science Center Lung Biology Committee.  She plays several roles within AACR, including being an invited member of the Science Policy and Government Affairs committee and Chair of the AACR Tobacco Products and Cancer Subcommittee. In April 2023, Dr. Lovly was elected to serve a three-year term on the prestigious AACR Board of Directors.

Dr. Lovly has received career development awards from the Damon Runyon Foundation, the V Foundation, LUNGevity, Lung Cancer Research Foundation, AACR, and ASCO. In 2021, Dr. Lovly was awarded the ECOG-ACRIN Cancer Research Group Young Investigator Award. In 2022, she was awarded the GO2 Foundation Asclepios Award honoring research pioneers in the fight to end lung cancer.  She is frequently invited to present her work at national and international conferences and symposia, with > 150 invited talks, including endowed lecture series at cancer centers including Cleveland Clinic and Dana Farber.

In addition to cancer research, Dr. Lovly’s other passion is volunteering at her local city animal shelter, working with and supporting the homeless dogs of Nashville.